Measuring inflammatory markers during routine blood tests in people with chronic obstructive pulmonary disease (COPD) could acute exacerbations at risk of experiencing worse outcomes, according to a small literature review study. Specifically, the researchers suggest measuring the neutrophil-to-lymphocyte ratio (NLR) — an indicator of systemic or body-wide inflammation. The…
Pulmonx and the American Lung Association have partnered to educate patients and healthcare providers about treatment options, including endobronchial valves that can help people breathe easier who have severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Led by the American Lung Association, the Treating Severe COPD…
AstraZeneca has acquired the exclusive rights to develop and commercialize C4X Discovery’s oral NRF2 activator for treating chronic obstructive pulmonary disease (COPD) and other inflammatory and respiratory diseases. The activator program aims to harness the antioxidant and anti-inflammatory properties of NRF2 in these conditions, although COPD will be…
Pulmonx has won the green light in Japan to market its Zephyr Endobronchial Valve, a bronchoscope-placed device designed to help people breathe easier who have severe emphysema, a form of chronic obstructive pulmonary disease (COPD). With the OK from the Japanese Ministry of Health, Labour and Welfare…
The U.S. Food and Drug Administration (FDA) has authorized EpiEndo Pharmaceuticals to conduct a Phase 2a clinical trial of its antibiotic treatment EP395 in people with chronic obstructive pulmonary disease (COPD). It will be the first test of the experimental therapy in COPD patients. The clinical trial…
Therapeutic Solutions International (TSOI) has launched a pharmaceutical spin-off — Breathe Biologics — that will take the lead in developing and marketing therapies for chronic obstructive pulmonary disease (COPD), including JadiCell, its investigational stem cell therapy. TSOI has licensed to Breathe Biologics the investigational new drug (IND) application for…
AlphaID At Home, a screening kit to detect alpha-1-antitrypsin deficiency (alpha-1), has been cleared by the U.S. Food and Drug Administration (FDA). The free, direct-to-consumer screening kit developed by Grifols will enable adults in the U.S. to determine their genetic risk of developing lung or liver disease linked to…
From exercising and promoting early diagnoses, to sporting orange and sharing resources on social media, supporters are marking COPD Awareness Month — observed each November — and working to call attention to chronic obstructive pulmonary disease (COPD). The chronic lung disorder affects 384 million people worldwide, including 16…
Mortality rates associated with chronic obstructive pulmonary disease (COPD) were declining in men but rising among women in many countries as of 2019, according to a recent study. This shift is likely related to changes in smoking habits, with smoking generally declining in men but being more variable among…
Signify Health, a U.S. healthcare platform, has added spirometry testing for chronic obstructive lung disease (COPD) to its in-home diagnostic and preventive services. The company began offering spirometry testing in select locations earlier this year, with at-home evaluations available to Medicare Advantage and Medicaid plan members. “In-home…
Get regular updates to your inbox.